KCRS.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2007-09-28
Share capital
506 246,20 PLN
Activity description

ICON plc provides clinical research outsourcing services for biotech and small to mid-sized biopharma companies. It supports programs from early-phase design through market access, and offers consulting, advisory services, and tailored clinical development. The company also focuses on areas such as genomic breakthroughs, first-in-class immunotherapies, and drug development in APAC and China.

Registered address
ul. Prosta 68, 00-838 Warszawa, Poland
Website
kcrcro.comWebsite active
Social media
Electronic delivery address
AE:PL-89455-60296-DJADD-26

Financials

The financial statement for 2024 has not yet been filed with the Financial Document Repository (past deadline).

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2023.

Results vs industry

Revenue
This companyUSD 43.60mMedianUSD 126.89kAverageUSD 4.67m
Net profit
This companyUSD 489.33kMedianUSD -19.64AverageUSD 371.62k
Operating costs
This companyUSD 42.03mMedianUSD 165.83kAverageUSD 4.01m
Assets
This companyUSD 27.86mMedianUSD 251.40kAverageUSD 7.40m

Industry

Bank accounts

Registered as a VAT taxpayer on 2001-12-04. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication dateEvent
May 7, 2024Commercial Companies Code notice
Nov 21, 2019Financial statement published
Aug 1, 2018Bankruptcy notice
Nov 17, 2014Bankruptcy notice
Nov 3, 2014Financial statement published

Public aid

No public aid cases recorded in the last 10 years.

European Funds

StartProjectEU co-financingProgramme
2010-07-01
Health-f2-2010-261358/paddington
$1,772,643FP7 Cooperation

Tenders

No recorded participation in tenders.

Authorized Representatives

Emer Lyons — Management Board Member
Simon Hollywood — Management Board Member
Simon Holmes — Management Board Member

Manner of representation

Each member of the management board is authorized to make declarations of will on behalf of the company independently.

Supervisory board

Diarmaid Cunningham — Supervisory Board Member
Julian Hayes — Supervisory Board Member
James Houlihan — Supervisory Board Member

Beneficial owners

PersonRights
Simon Hollywood (46)
Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5).
Simon Holmes (60)
Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5).
Emer Lyons (48)
Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5).

Subsidiaries

NameShare valueStake
Curandussp. z o.o.
13,506.21 USD100%
KCR Placementsp. z o.o.
13,506.21 USD100%

Competitors

NameRevenueWebsite
Polpharma BiologicsS.A.$19,057,541.37polpharmabiologics.com
ArdigenS.A.$12,513,309.89ardigen.com
Sidlysp. z o.o.$4,977,649.42sidly.eu

Change history

DateEvent
2025-04-28Address change (Postępu 6, 02-676, Warszawa → Ul. Prosta 68, 00-838, Warszawa)
2025-04-28PKD change (Removed: 46.46.Z, 69.20.Z, 70.10.Z, 70.21.Z, 70.22.Z, 72.19.Z, 73.20.Z, 82.30.Z, 85.60.Z, 86.90.E; Added: 69.20.A, 69.20.B, 70.10.B, 70.20.Z, 72.10.Z, 73.30.B)
2024-07-18Share capital change (571,666.20 PLN → 506,246.20 PLN)
2018-05-21Share capital change (700,000.00 PLN → 571,666.20 PLN)
2015-01-12PKD change (Removed: 46.18.Z, 46.19.Z, 85.59.B)

FAQ

Last updated: 2026-03-22